Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

Table 1 Sample selection and attrition

Patients	Remaining
Patients	N	%
Patients^*	151,118
Patients with continuous enrollment (index date minus 365 to index date)	72,978	48.3
Patients with index cancer (BC, CRC, LC, NHL, Ovarian)	18,186	24.9
Patients meeting criteria for eligible course	10,219	56.2
Patients without stem cell transplant	10,207	99.9
Patients without use of nursing facility	9,989	97.9
Patients with G-CSF use during at least one cycle	4,684	46.9
Patients without radiation on index date	4,531	96.7
Patients without more than one primary cancer site^†	3,958	87.4
Patients with prophylactic G-CSF use in at least one cycle	3,535	89.3
Patients with prophylactic pegfilgrastim use	3,372	95.4
Patients with prophylactic filgrastim use	163	4.6
Patient-cycles with G-CSF prophylaxis in 3,535 patients	12,056
Pegfilgrastim	11,683	96.9
Filgrastim	373	3.1
Patient-cycles with G-CSF prophylaxis [included up to the 9^th cycle]	11,968
Pegfilgrastim	11,597	96.9
Filgrastim	371	3.1

BC – breast cancer, CRC – colorectal cancer, LC – lung cancer, and NHL – non-Hodgkin’s lymphoma.
^* Patients with any evidence of chemotherapy from January 1, 2005 to February 28, 2009 (index date set to first administration) and no chemotherapy from index date −365 to index date −1.
^† Primary cancers defined as: 140.xx – 172.xx, 174.xx – 195.xx and 199.xx – 208.xx.

ISSN: 1471-2407